AZN vs SRBK · P/E 28, $288.38B cap vs P/E 33, rev $46.3M
AstraZeneca PLC (AZN) versus SR Bancorp, Inc. Common stock (SRBK) — a side-by-side from cached financials, not a winner call.
AstraZeneca PLC (AZN) is a drug manufacturers - general company listed on US.
SR Bancorp, Inc. Common stock (SRBK) is a banks - regional company listed on NASDAQ.
AZN does not have a complete income-statement cache yet.
Latest reported SRBK revenue for 2025-06-30 was $46.3M. Net income was $5.1M. Revenue was up 13.3% from 2024-06-30 to 2025-06-30. SRBK currently screens at market cap $140.4M and trailing P/E 32.6.
AZN currently screens at market cap $288.38B and trailing P/E 28.0. SRBK currently screens at market cap $140.4M and trailing P/E 32.6.
Not investment advice. Open the AZN and SRBK stock pages for the full models.
Not investment advice.